EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination

Marianna Pócsi, Zsolt Fejes, Zsolt Bene, Attila Nagy, István Balogh, Margarida D Amaral, Milan Macek, Béla Nagy

Journal of Cystic Fibrosis · 2023

DOI: 10.1016/j.jcf.2023.04.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von Marianna Pócsi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Laki Kálmán Doctoral School, Faculty of Medicine, …. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research, Development and Innovation Office, Cystic Fibrosis Foundation, Ministerstvo Školství, Mládeže a Tělovýchovy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We previously documented that elevated HE4 plasma concentration decreased in people with CF (pwCF) bearing the p.Gly551Asp-CFTR variant in response to CFTR modulator (CFTRm) ivacaftor (IVA), and this level was inversely correlated with the FEV1% predicted values (ppFEV1). Although the effectiveness of lumacaftor (LUM)/IVA in pwCF homozygous for the p.Phe508del-CFTR variant has been evaluated, plasma biomarkers were not used to monitor treatment efficacy thus far. METHODS: Plasma HE4 concentration was examined in 68 pwCF drawn from the PROSPECT study who were homozygous for the p.Phe508del-CFTR variant before treatment and at 1, 3, 6 and 12 months after administration of LUM/IVA therapy. Plasma HE4 was correlated with ppFEV1 using their absolute and delta values. The discriminatory power of delta HE4 was evaluated for the detection of lung function improvements based on ROC-AUC analysis and multiple regression test. RESULTS: HE4 plasma concentration was significantly reduced below baseline following LUM/IVA administration during the entire study period. The mean change of ppFEV1 was 2.6% (95% CI, 0.6 to 4.5) by 6 months of therapy in this sub-cohort. A significant inverse correlation between delta values of HE4 and ppFEV1 was observed especially in children with CF (r=-0.7053; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisChildHumansCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesAminopyridinesDrug CombinationsHomozygoteChloride Channel AgonistsMutationQuinolones

Stichwörter der Autor:innen

BiomarkerCystic fibrosisHE4Lumacaftor/ivacaftorSweat chlorideppFEV1

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesAminopyridinesDrug CombinationsChloride Channel AgonistsivacaftorQuinoloneslumacaftorCFTR protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Laki Kálmán Doctoral School, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, Debrecen, Hungary.
  • Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen,…
  • BioISI - Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.

Förderung

  • National Research, Development and Innovation Office
  • Cystic Fibrosis Foundation
  • Ministerstvo Školství, Mládeže a Tělovýchovy
  • Fundação para a Ciência e a Tecnologia
  • Ministerstvo Zdravotnictví Ceské Republiky
  • Hungarian Scientific Research Fund

Zitieren

APA

Pócsi, M., Fejes, Z., Bene, Z., Nagy, A., Balogh, I., Amaral, M. D., Macek, M., & Nagy, B. (2023). Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.04.001

Vancouver

Pócsi M, Fejes Z, Bene Z, Nagy A, Balogh I, Amaral MD, et al. Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.04.001

BibTeX
@article{Pcsi2023,
  author = {Pócsi, Marianna and Fejes, Zsolt and Bene, Zsolt and Nagy, Attila and Balogh, István and Amaral, Margarida D and Macek, Milan and Nagy, Béla},
  title = {Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination},
  journal = {Journal of Cystic Fibrosis},
  year = {2023},
  doi = {10.1016/j.jcf.2023.04.001}
}
Kostenlos starten →